quinazolines has been researched along with Urinary Retention in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (17.95) | 18.2507 |
| 2000's | 28 (71.79) | 29.6817 |
| 2010's | 3 (7.69) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Ergakov, DV; Martov, AG | 1 |
| Carrillo-Ruiz, JD; González-Valle, JC; Guzman-Esquivel, J; Labra-Salgado, IR; Maldonado-Ávila, M; Manzanilla-García, HA; Rosas-Nava, E; Sierra-Ramírez, JA | 1 |
| Fisher, E; Omar, MI; Subramonian, K | 1 |
| Kara, O; Yazici, M | 1 |
| Chodchoy, V; Kongkanand, A; Lojanapiwat, B; Pumpaisanchai, S; Ratana-Olarn, K; Sae-Tang, P; Taweemonkongsap, T | 1 |
| Consigliere, D; Li, MK; Macalalag, M; Tibung, MJ; Tiong, HY | 1 |
| Subramonian, K; Zeif, HJ | 1 |
| Biyani, S; Elmasry, Y; Flannigan, GM; Palit, V; Puri, R; Shah, T | 1 |
| Nordling, J; Roehrborn, CG; Van Kerrebroeck, P | 1 |
| O'Leary, MP | 1 |
| Wyllie, MG | 1 |
| Hargreave, TB; McNeill, SA | 1 |
| Byrne, DJ; McNeill, AS; Rizvi, S | 1 |
| Hargreave, TB; McNeill, SA; Roehrborn, CG | 1 |
| Jefferson, K; Okeke, A; Persad, R | 1 |
| Biyani, CS; Browning, AJ; Taylor, J | 1 |
| Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, J | 1 |
| Annemans, L; Cleemput, I; Hargreave, T; Lamotte, M; McNeill, A | 1 |
| Roehrborn, CG | 2 |
| Biyani, CS; Elmasry, Y; Flannigan, GM; Palit, V; Puri, R; Sarkar, R; Shah, T | 1 |
| Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ | 2 |
| Fitzpatrick, JM | 1 |
| Emberton, M | 1 |
| De La Taille, A; Desgrandchamps, F; Doublet, JD | 1 |
| Alcaraz, A; Elhilali, M; Emberton, M; Lukacs, B; Matzkin, H; Vallancien, G | 1 |
| Brown, DJ; Mariappan, P; McNeill, AS | 1 |
| Byrne, DJ; Goodman, CM; Gopi, SS; Robertson, A | 1 |
| Hansen, BJ; Mensink, HJ; Meyhoff, HH; Nordling, J; Walter, S | 1 |
| Attali, P; Bensadoun, H; Delauche-Cavallier, MC; Jardin, A; Stalla-Bourdillon, A | 1 |
| Buzelin, JM; Delauche-Cavallier, MC; Geffriaud-Ricouard, C; Roth, S; Santoni, JP | 1 |
| Boutkan, H; Breslau, PJ; Burger, DH; Kappetein, AP | 1 |
| Angel, I; Buzelin, JM; Delauche Cavallier, MC; Martin, D | 1 |
| Daruwala, PD; Hargreave, TB; McNeill, SA; Mitchell, ID; Shearer, MG | 1 |
| Comet, D; Grange, JC; Lukacs, B; McCarthy, C | 1 |
| Comet, D; Grange, JC; Lukacs, B | 1 |
| McNeill, SA | 1 |
| Attali, P; Bensadoun, H; Delauche-Cavallier, MC; Jardin, A | 1 |
6 review(s) available for quinazolines and Urinary Retention
| Article | Year |
|---|---|
The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Device Removal; Doxazosin; Humans; Indoles; Male; Quinazolines; Randomized Controlled Trials as Topic; Recovery of Function; Sulfonamides; Tamsulosin; Urinary Catheterization; Urinary Retention; Urination | 2014 |
Alpha blockers prior to removal of a catheter for acute urinary retention in adult men.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Device Removal; Humans; Male; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Tamsulosin; Urinary Catheterization; Urinary Retention; Urination | 2009 |
Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Animals; Disease Progression; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Quality of Life; Quinazolines; Rabbits; Severity of Illness Index; Transurethral Resection of Prostate; Urethral Obstruction; Urinary Retention | 2003 |
The natural history of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Disease Progression; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; Prostatectomy; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urinary Retention | 2006 |
Definition of at-risk patients: dynamic variables.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Disease Progression; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urination | 2006 |
Does acute urinary retention respond to alpha-blockers alone?
Topics: Acute Disease; Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urinary Retention | 2001 |
18 trial(s) available for quinazolines and Urinary Retention
| Article | Year |
|---|---|
A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth.
Topics: Acute Disease; Adrenergic alpha-1 Receptor Antagonists; Aged; Device Removal; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Recovery of Function; Sulfonamides; Tamsulosin; Urinary Catheterization; Urinary Retention; Urination | 2014 |
Is the double dose alpha-blocker treatment superior than the single dose in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia?
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Dizziness; Drug Therapy, Combination; Headache; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Urinary Retention | 2014 |
Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Prostatic Hyperplasia; Quinazolines; Urinary Catheterization; Urinary Retention | 2009 |
Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Catheterization; Delayed-Action Preparations; Double-Blind Method; Humans; Male; Middle Aged; Quinazolines; Urinary Retention | 2002 |
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Erectile Dysfunction; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sexual Dysfunction, Physiological; Treatment Outcome; Urinary Retention | 2003 |
Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Quinazolines; Single-Blind Method; Urinary Retention | 2004 |
Prostate size influences the outcome after presenting with acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Cohort Studies; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Prostate; Prostatic Hyperplasia; Quinazolines; Treatment Failure; Urinary Retention | 2004 |
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Biomarkers; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Emergencies; Humans; Life Tables; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Recurrence; Urinary Catheterization; Urinary Retention | 2005 |
Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Organ Size; Probability; Prostatic Hyperplasia; Quinazolines; Statistics, Nonparametric; Treatment Failure; Urinary Retention | 2006 |
Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Quinazolines; Risk Factors; Treatment Outcome; Urinary Retention | 2006 |
A prospective pilot study to validate the management protocol for patients presenting with acute urinary retention: a community-based, nonhospitalised protocol.
Topics: Adrenergic alpha-Antagonists; Aged; Catheterization; Community Health Services; Humans; Male; Middle Aged; Outpatients; Pilot Projects; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Quinazolines; Treatment Outcome; Urinary Retention | 2006 |
Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urodynamics | 1994 |
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Follow-Up Studies; Heart Rate; Humans; Long-Term Care; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urination; Urodynamics | 1994 |
Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Delayed-Action Preparations; Double-Blind Method; Humans; Hypertension; Male; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urinary Retention; Urination | 1997 |
Prevention of urinary retention after general surgery: a controlled trial of carbachol/diazepam versus alfusozine.
Topics: Adrenergic alpha-Antagonists; Aged; Carbachol; Diazepam; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Incidence; Male; Muscle Relaxants, Central; Parasympathomimetics; Postoperative Complications; Quinazolines; Treatment Failure; Urinary Retention; Urination | 1997 |
Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Delayed-Action Preparations; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Urinary Retention | 1999 |
History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years.
Topics: Adrenergic alpha-Antagonists; Aged; Cohort Studies; Disease Progression; Family Practice; Follow-Up Studies; Humans; Male; Prostatic Hyperplasia; Quinazolines; Time Factors; Urinary Retention | 2000 |
Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Evaluation; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Severity of Illness Index; Time Factors; Urinary Retention; Urination | 1991 |
15 other study(ies) available for quinazolines and Urinary Retention
| Article | Year |
|---|---|
[The use of alfuzosin in the treatment of patients with acute urinary retention].
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Transurethral Resection of Prostate; Urinary Retention | 2020 |
Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Ejaculation; Humans; Male; Middle Aged; Penile Erection; Prostatic Hyperplasia; Quinazolines; Urinary Retention | 2009 |
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Prostatic Hyperplasia; Quinazolines; Randomized Controlled Trials as Topic; Urinary Retention | 2003 |
Re: alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Drug Administration Schedule; Humans; Quinazolines; Urinary Retention | 2005 |
Re: Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Drug Administration Schedule; Humans; Quinazolines; Urinary Retention | 2005 |
Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urination Disorders | 2005 |
The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Decision Support Techniques; Drug Costs; Emergency Treatment; Follow-Up Studies; Humans; Male; Middle Aged; Monte Carlo Method; Prostatectomy; Prostatic Hyperplasia; Quinazolines; United Kingdom; Urinary Retention | 2005 |
Long term follow up of men with Alfuzosin who voided successfully following acute urinary retention*.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Follow-Up Studies; Humans; Male; Quality of Life; Quinazolines; Transurethral Resection of Prostate; Treatment Failure; Urinary Retention | 2005 |
Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.
Topics: Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Libido; Male; Middle Aged; Patient Satisfaction; Penile Erection; Prostatic Hyperplasia; Quality of Life; Quinazolines; Treatment Outcome; Urinary Retention | 2006 |
The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Catheters, Indwelling; Cross-Sectional Studies; France; Health Care Surveys; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Stents; Treatment Outcome; Urinary Catheterization; Urinary Retention | 2006 |
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Urinary Retention; Urination Disorders | 2006 |
Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Endosonography; Humans; Male; Middle Aged; Organ Size; Predictive Value of Tests; Premedication; Prognosis; Prospective Studies; Prostate; Prostatic Hyperplasia; Quinazolines; Statistics as Topic; Treatment Outcome; Urinary Bladder Neck Obstruction; Urinary Catheterization; Urinary Retention; Urodynamics | 2007 |
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Erectile Dysfunction; Humans; Male; Nocturia; Patient Satisfaction; Prostatic Hyperplasia; Prostatism; Quality of Life; Quinazolines; Sexual Dysfunction, Physiological; Treatment Outcome; Urinary Retention | 2008 |
Clinical uroselectivity: evidence from patients treated with slow release alfuzosin for symptomatic benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Delayed-Action Preparations; Dose-Response Relationship, Drug; Humans; Male; Prostatic Hyperplasia; Quinazolines; Urinary Retention | 1998 |
One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Family Practice; Follow-Up Studies; Humans; Male; Middle Aged; Postoperative Complications; Prostatectomy; Prostatic Hyperplasia; Quality of Life; Quinazolines; Recurrence; Sickness Impact Profile; Urinary Retention; Urodynamics | 2000 |